This week we have several issues to watch. Earnings season is mostly done but there are still many on deck in this week’s unusual suspects. Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN), Eli Lilly & Co. (NYSE: LLY) and Alkermes, Inc. (NASDAQ: ALKS) are still in the ‘pending’ status for FDA. Evergreen Solar (NASDAQ: ESLR), Energy Conversion Devices (NASDAQ: ENER), and Dr. Pepper Snapple Group, Inc. (NYSE: DPS) are all touched in Barron’s. Next week we have AthenaHealth, Inc. (NASDAQ: ATHN), Sequenom In.c (NASDAQ: SQNM), AMBAC Financial (NYSE: ABK), Nike Inc. (NYSE: NKE), FedEx Corporation (NYSE: FDX), GameStop Corp. (NYSE: GME), 3Com (NASDAQ: COMS) and Palm, Inc. (NASDAQ: PALM) are all scheduled to report earnings. We have handicapped the events with basic previews and Thomson Reuters, and we have added color for traders on what else to look for outside of the numbers.
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) did not release an FDA decision on Friday on its site nor via any of the wires that we read reporting on one. This was over its data for Byetta, the first ‘once weekly’ diabetes treatment for Type II diabetes. Partners Eli Lilly & Co. (NYSE: LLY) and Alkermes, Inc. (NASDAQ: ALKS) are also in. Lilly’s Alkermes is the delivery technology that allows for a delivery over the course of a week.
Barron’s has a piece out over the weekend cautioning the investor world about the big risks in solar companies which may be very vulnerable to supply/ demand issues. Eric Savitz in Technology Trader singled out Evergreen Solar (NASDAQ: ESLR) and the Uni-Solar division of Energy Conversion Devices (NASDAQ: ENER) as being vulnerable. It is hard to imagine that these won’t be hit on Monday morning.